nach oben

Erschienen in:

01.10.2010 | Original Article

Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors

verfasst von: Yasuhito Fujisaka, Yasuhide Yamada, Noboru Yamamoto, Toshio Shimizu, Yutaka Fujiwara, Kazuhiko Yamada, Tomohide Tamura, Hiroyuki Watanabe, Yu-Nien Sun, Michael B. Bass, Mitsuo Seki

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to investigate the safety and pharmacokinetics of motesanib (AMG 706), a small-molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and c-Kit in Japanese patients with advanced solid tumors.

Methods

Patients were administered motesanib orally once daily (QD) at doses of 50, 100, and 125 mg QD. The total study duration for each patient consisted of three cycles of 28 days per cycle. The primary endpoints were the incidence of dose-limiting toxicities (DLTs), estimation of the maximum tolerated dose (MTD), and assessment of pharmacokinetic parameters of motesanib.

Results

Fifteen patients were enrolled and received motesanib. No DLTs were observed and, therefore, the MTD was not reached. Motesanib had acceptable toxicity at doses up to 125 mg QD. The pharmacokinetics of motesanib appears to be dose proportional. No objective responses per RECIST were observed. However, all 15 patients achieved stable disease, and five patients had durable (>24 weeks) stable disease.

Conclusions

The results of this study demonstrate that motesanib is tolerable in Japanese patients at doses up to 125 mg QD.

Kato H, Sobue T, Katanoda K et al (2007) Cancer statistics in Japan 2007. National Cancer Center, Tokyo

Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18PubMed

Arii S (2006) Tumor angiogenesis and antiangiogenic therapy: current status and perspective. Int J Clin Oncol 11:71–72CrossRefPubMed

Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanism of anti-tumour activity. Nat Rev Cancer 8:579–591CrossRefPubMed

Abrams TJ, Murray LJ, Pesenti E et al (2003) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011–1021PubMed

Wilmes LJ, Pallavicini MG, Fleming LM et al (2007) AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 25:319–327CrossRefPubMed

Wilhelm SM, Carter C, Tang L et al (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109CrossRefPubMed

Wedge SR, Ogilvie DJ, Dukes M et al (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645–4655PubMed

Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516–2524CrossRefPubMed

10.

Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23:3243–3256CrossRefPubMed

11.

Rugo HS, Herbst RS, Liu G et al (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474–5483CrossRefPubMed

12.

Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550CrossRefPubMed

13.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676CrossRefPubMed

14.

Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932–936CrossRefPubMed

15.

Yu J, Ustach C, Kim HR (2003) Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 36:49–59PubMed

16.

Wang D, Huang HJ, Kazlauskas A, Cavenee WK (1999) Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 59:1464–1472PubMed

17.

Polverino A, Coxon A, Starnes C et al (2006) AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66:8715–8721CrossRefPubMed

18.

Rosen LS, Kurzrock R, Mulay M et al (2007) Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:2369–2376CrossRefPubMed

19.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed

20.

Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35CrossRefPubMed

21.

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMed

22.

Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434CrossRefPubMed

23.

Bouloumie A, Schini-Kerth VB, Busse R (1999) Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 41:773–780CrossRefPubMed

24.

Pankaj B (2009) VEGF kinase inhibitors: how do they cause hypertension. Am J Physiol Regul Integr Comp Physiol 297:R1–R5

25.

Basser R, Hurwitz H, Barge A et al (2001) Phase 1 pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumors. Proc Am Soc Clin Oncol 20:396

26.

Eisen T, Ahmad T, Gore ME et al (2005) Phase I trial of BAY 43–9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. (#7508). Proc Am Soc Clin Oncol 23:16S

27.

Kulke M, Lenz HJ, Meropol NJ et al (2005) A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors. (#4008). Proc Am Soc Clin Oncol 23:16S

28.

Shah MA, Ilson D, Kelson DP (2005) Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan and bevacizumab-based therapy. J Clin Oncol 11:2574–2576CrossRef

29.

Zangari M, Anaisse E, Barlogie B et al (2001) Increased risk of deep venous thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614–1615CrossRefPubMed

Titel: Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors
verfasst von: Yasuhito Fujisaka
Yasuhide Yamada
Noboru Yamamoto
Toshio Shimizu
Yutaka Fujiwara
Kazuhiko Yamada
Tomohide Tamura
Hiroyuki Watanabe
Yu-Nien Sun
Michael B. Bass
Mitsuo Seki
Publikationsdatum: 01.10.2010
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 5/2010
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1243-y

Springer Medizin

Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors